pone.0266478.g005.tif (1.47 MB)

CB-5083 and cytarabine or venetoclax synergistically decrease AML cell survival.

Download (1.47 MB)
posted on 2022-04-06, 17:39 authored by Paweł P. Szczęśniak, Jan B. Heidelberger, Hubert Serve, Petra Beli, Sebastian A. Wagner

(A-D) THP-1 and MV4-11 cell survival was assessed in a 96-well format with increasing concentrations of CB-5083 and cytarabine or venetoclax. Following a 72-hour incubation, CellTiter-Blue Reagent was added and fluorescence/cell viability was assessed. Cell viability data was used as input for the SynergyFinder software to estimate synergy δ scores. Synergy landscape maps display δ scores for the indicated cells lines and drug combinations.